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Grip strength deficit is a measure of pain-induced functional disability in rheumatic disease. We tested
whether this parameter and tactile allodynia, the standard pain measure in preclinical studies, show
parallels in their response to analgesics and basic mechanisms. Mice with periarticular injections of
complete Freund's adjuvant (CFA) in the ankles showed periarticular immune infiltration and synovial
membrane alterations, together with pronounced grip strength deficits and tactile allodynia measured
with von Frey hairs. However, inflammation-induced tactile allodynia lasted longer than grip strength
alterations, and therefore did not drive the functional deficits. Oral administration of the opioid drugs
oxycodone (1e8 mg/kg) and tramadol (10e80 mg/kg) induced a better recovery of grip strength than
acetaminophen (40e320 mg/kg) or the nonsteroidal antiinflammatory drugs ibuprofen (10e80 mg/kg)
or celecoxib (40e160 mg/kg); these results are consistent with their analgesic efficacy in humans.
Functional impairment was generally a more sensitive indicator of drug-induced analgesia than tactile
allodynia, as drug doses that attenuated grip strength deficits showed little or no effect on von Frey
thresholds. Finally, ruthenium red (a nonselective TRP antagonist) or the in vivo ablation of TRPV1-
expressing neurons with resiniferatoxin abolished tactile allodynia without altering grip strength defi-
cits, indicating that the neurobiology of tactile allodynia and grip strength deficits differ. In conclusion,
grip strength deficits are due to a distinct type of pain that reflects an important aspect of the human
pain experience, and therefore merits further exploration in preclinical studies to improve the translation
of new analgesics from bench to bedside.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).complete Freund's adjuvant;
HPMC, hydroxypropyl meth-
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r Ltd. This is an open access article1. Introduction
Pain is an important global health problem, and there is a need
for new analgesics (Goldberg and McGee, 2011). However, despite
major advances in our understanding of pain mechanisms in recent
decades, there has been little translation of new analgesics from
bench to bedside (Barrett, 2015; Kissin, 2010; Mao, 2009).
The predictive validity of animal models of pain has been
intensely debated, and one possible reason for the limitedunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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used to evaluate pain and analgesia in experimental animals and
human patients (Cobos and Portillo-Salido, 2013; Mogil and Crager,
2004; Negus et al., 2006; Negus, 2013; Percie and Rice, 2014).
Ideally, for the purposes of translation, animal testing shouldmimic
as closely as possible routine clinical practice and clinical trials.
Standard outcome measures used in preclinical chronic pain
research have been adapted fromquantitative sensory testing (QST)
designed for the evaluation of patients with chronic pain, and von
Frey filaments are one of the most widely used QST instruments to
determine the mechanical pain threshold in preclinical research. In
human patients, QST procedures are used to detect sensory alter-
ations during neuropathic pain (e.g. Bennett, 2001; Bouhassira
et al., 2005; Moharic et al., 2012). However, the use of QST in pa-
tients with rheumatic diseases is rare. To our knowledge only three
published studies used von Frey filaments in human patients with
rheumatoid arthritis (Hendiani et al., 2003; Morris et al., 1997; van
Laarhoven et al., 2013), one of the most worrisome painful condi-
tions that occurs with joint inflammation (Lee, 2013; Scott et al.,
2000). This low number of clinical reports with von Frey testing
is in marked contrast to the hundreds of preclinical studies that
have used this technique in animal models of joint pain.
Pain is a complex phenomenon. Part of the core of the human
pain phenotype includes alterations in physical functioning, which
negatively impacts several aspects of daily life in patients with
painful diseases (Romera et al., 2011; Turner et al., 2005). Because of
the important relationship between pain and physical functioning,
one set of consensus-based recommendations advocates
measuring physical function as one of themain outcomes in clinical
trials of treatments for pain (Dworkin et al., 2008). In this
connection, grip strength has been widely and routinely evaluated
for decades in rheumatology as a functional measure in patients
with joint inflammation (e.g. Bijlsma et al., 1987; Lee, 2013; Pincus
and Callahan,1992), and remarkably, it is known to correlate to pain
(Callahan et al., 1987; Fraser et al., 1999; Overend et al., 1999).
Despite the widespread use of grip strength in rheumatology, this
outcome is poorly characterized as a pain measure in experimental
animals. However, as noted above, preclinical studies of tactile
allodynia are abundant. It is known that transient receptor poten-
tial (TRP) channels or TRP-expressing nociceptors participate in
inflammatory cutaneous hypersensitivity (Szallasi et al., 2007), but
much less is known about the neurobiological mechanisms leading
to pain-induced functional disability.
In light of these antecedents, we aimed to compare the sensi-
tivity of grip strength in mice with joint inflammation vs. inflam-
matory tactile allodynia to the effects of several analgesic drugs of
different pharmacological classes, and tested whether the appear-
ance of grip strength deficits and tactile allodynia arose from the
same mechanisms.
2. Material and methods
2.1. Experimental animals
Experiments were done in 680 female CD1 mice (Charles River,
Barcelona, Spain) weighing 28e30 g at the beginning of the study.
We choose female animals because it has been reported that
women may be at greater risk for pain-related disability than men
(e.g. Unruh, 1996; Stubbs et al., 2010), but no previous studies have
evaluated grip strength as a measure of pain-induced functional
disability in female animals. Animals were tested randomly
throughout the estrous cycle. They were housed in colony cages
with free access to food and water prior to the experiments, and
were kept in temperature- and light-controlled rooms (22 ± 2 C,
and lightedark cycle of 12 h). The experiments were done duringthe light phase (from 9:00 a.m. to 3:00 p.m.). All experimental
protocols were carried out in accordance with international stan-
dards (European Communities Council directive 2010/63), and
were approved by the Research Ethics Committee of the University
of Granada. To decrease the number of animals in this study, we
used the samemice for behavioral studies, histological analysis and
immunostaining, when possible.
2.2. CFA-induced periarticular inflammation
Mice were injected periarticularly with complete Freund's
adjuvant (CFA) (Sigma-Aldrich, Madrid, Spain) or sterile physio-
logical saline (0.9% NaCl) as a control around the tibiotarsal joint.
CFA (or saline) was administered subcutaneously in two separate
injections to the inner and outer side of the joint in a volume of 10
or 15 mL/injection (20 or 30 mL/paw), to obtain homogeneous
inflammation (Chen et al., 2009; Lolignier et al., 2011). We used a
1710 TLL Hamilton microsyringe (Teknokroma, Barcelona, Spain)
with a 30½-gauge needle under isoflurane anesthesia (IsoVet®, B.
Braun, Barcelona, Spain). CFA-treated mice had prominent inflam-
mation that appeared to be restricted to the administration site and
nearby areas (heel), whereas the paw pad did not appear to be
affected. This allowed us to test the mechanical threshold in these
two distinct areas. See “Results” for details. Because weight loss or
delayed weight gain are considered signs of ongoing distress
(Blackburn-Munro, 2004), body weight was monitored daily to
ensure that our protocol did not induce excessive harm to the an-
imals. Inflammatory edema was monitored by measuring ankle
thickness with an electronic caliper (e.g. Croci and Zarini, 2007).
2.3. Drugs and drug administration
We used the following prototypic analgesics: the nonsteroidal
antiinflammatory drug (NSAID) ibuprofen sodium salt (10e80 mg/
kg), the cyclooxygenase-2 (COX-2) inhibitor celecoxib (40e160 mg/
kg), and acetaminophen (40e320 mg/kg) (all from Sigma-Aldrich),
and the opioids tramadol (10e80 mg/kg) and oxycodone hydro-
chloride (1e8 mg/kg) (supplied by Laboratorios Esteve, Barcelona,
Spain). We also tested the effects of the antispastic baclofen
(5e20 mg/kg) (Sigma-Aldrich). All drugs were dissolved in 0.5%
hydroxypropyl methylcellulose (HPMC) with the exception of cel-
ecoxib and acetaminophen, which were suspended in HPMC sup-
plemented with 1% Tween 80 (both from Sigma-Aldrich). These
drugs or their solvents were administered orally (p.o.) in a volume
of 10 mL/kg.
In addition, we also tested the effects of ruthenium red (1e2mg/
kg) (Sigma-Aldrich), a nonselective TRP antagonist (St Pierre et al.,
2009). Ruthenium red was dissolved in saline and administered
subcutaneously (s.c.) into the interscapular zone in a volume of
5 mL/kg. The control group received an equal volume of saline.
In all cases, behavioral evaluations after drug administration
were recorded by an observer blinded to the treatment.
2.4. In vivo ablation of TRP vanilloid 1 (TRPV1)-expressing
nociceptive neurons
We used resiniferatoxin (RTX) to selectively ablate TRPV1-
expressing neurons. The drug (Tocris Cookson Ltd, Bristol, UK)
was dissolved in 10% Tween 80 and 10% ethanol in normal saline.
Animals received a single dose of RTX (50 mg/kg) via intraperitoneal
injection, which has been previously reported to ablate all pe-
ripheral TRPV1þ neurons (Hsieh et al., 2012). The control group
received an equal volume of vehicle. All procedures were done
under isoflurane anesthesia to minimize distress, 5 days before
behavioral testing or sample collection.
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Grip strength was measured with a computerized grip strength
meter (Model 47200, Ugo-Basile, Varese, Italy). The apparatus
consisted of a T-shaped metal bar connected to a force transducer.
To measure grip strength in the hindpaws of the mice, the exper-
imenter held the mouse gently by the base of the tail, allowing the
animal to grasp the metal bar with its hindpaws. To prevent mice
from gripping the metal bar with their forepaws during the
recording, the animals were first allowed to grasp a wire mesh
cylinder with their forepaws. As soon as the mice grasped the
transducer metal bar with their hindpaws, the experimenter pulled
the animals backwards by the tail until grip was lost (see Supple-
mental Video, which demonstrates the procedure used to measure
hindlimb grip strength). The peak force of each measurement was
automatically recorded in grams (g) by the device. Hindlimb grip
strength in each mouse was measured in triplicate. Basal grip
strength values were recorded for each animal as the average of
two determinations on different days before the administration of
CFA or saline. This value was considered as 100% of grip strength
and used as a reference for subsequent determinations.
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.neuropharm.2017.07.029.2.6. Measurement of von Frey threshold
Mechanical allodynia to a punctate stimulus was determined
with a slight modification of a previously described method
(Chaplan et al., 1994). Briefly, animals were acclimated for 2 h in
methacrylate test compartments (7.5 cm wide  7.5 cm
long 15 cm high) placed on an elevatedmesh-bottomed platform,
to provide access to the plantar surface of the hindpaws. Plantar
stimulation is the standard site of application of von Frey filaments
in animals with joint inflammation (e.g. Nieto et al., 2015;
Mangione et al., 2016). A logarithmic series of calibrated von Frey
monofilaments (Stoelting, Wood Dale, IL, USA), with bending forces
that ranged from 0.02 to 1.4 g, were applied using the upedown
paradigm, starting with the 0.6 g filament. Filaments were applied
two times for 2e3 s, with inter-application intervals of at least 30 s
to avoid sensitization to themechanical stimuli. The response to the
filament was considered positive if immediate licking/biting,
flinching or rapid withdrawal of the stimulated paw was observed.
As for grip strength determinations, basal values were recorded for
each animal as the average of two determinations on different days,
before the administration of CFA or saline. This value was consid-
ered 100% of the von Frey threshold and used as a reference for
subsequent determinations.2.7. Locomotor activity measurements
Ambulatory locomotionwasmeasuredwith an infrared detector
(Med associated Inc., St. Albans, VT, USA) equipped with 48 infrared
photocell emitters and detectors, according to a previously
described method (Sanchez-Fernandez et al., 2013) with slight
modifications. Briefly, animals were placed individually in trans-
parent evaluation chambers (27.5 cmwide  27.5 cm long  20 cm
high) and the distance traveled (horizontal activity) and the num-
ber of rears (vertical activity) were recorded during 30 min. Ani-
mals were tested only once to avoid habituation to the evaluation
chambers, which markedly decreases their locomotor activity. All
experiments were done in a sound-proofed room with dim light
(7e10 lux; Luxometer SM700, Milkwaukee 4 Electronics Kft.,
Szeged, Hungary). No experimenters were present in the testing
room during the evaluation period.2.8. Histology
Mice were anesthetized with isoflurane (IsoVet®, B. Braun,
Barcelona, Spain) and perfused intracardially with 20 mL saline
followed by 4% formaldehyde solution. After perfusion, the paws
were dissected and fixed with 10% buffered formalin for 48 h at
room temperature. Joints were then decalcified in Anne Morse
solution (50 mL formic acid and 50 mL 20% sodium citrate) at room
temperature for 14 days. Next, they were sectioned longitudinally,
dehydrated with alcohol, and embedded in paraffin. We used a
similar protocol to stain paw pad samples, but obtained the tissue
with a 3-mm punch, and omitted the decalcification step. Tissue
sections (7e10 mm) were stained with hematoxylin and eosin.
Images were acquired with a Nikon Eclipse 50i microscope equip-
ped with a DS-Ri1 camera.
2.9. Immunohistochemistry
Mice were transcardially perfused as above, and the L4 dorsal
root ganglion and the spinal cord lumbar enlargement were
dissected, postfixed, dehydrated and embedded in paraffin using
standard procedures. Tissue sections (5 mm) were deparaffinized in
xylol (Panreac Quimica, Castellar del Valles, Spain) and rehydrated.
Antigens were retrieved by steam heating with 1% citrate buffer.
Sections were incubated for 1 h in blocking solution (5% normal
donkey serum, 0.3% Triton X-100, 0.1% Tween 20 in Tris buffer so-
lution). Then the slices were incubated for 1 h at room temperature
with a goat anti-TRPV1 antibody (sc-12498, 1:100, Santa Cruz
Biotechnology, Inc., Heidelberg, Germany) in blocking solution.
After incubation, the sections were washed three times for 10 min
and incubated for 1 h with the secondary donkey anti-goat Alexa
Fluor-488 antibody (A11055, 1:500, Life Technologies, Alcobendas,
Spain) and a conjugated mouse anti-NeuN antibody (MAB377A5,
1:500, Merck Millipore, Madrid, Spain). The slices were then
washed three times for 10 min and mounted with ProLong® Gold
Antifade Mountant (Life Technologies, Alcobendas, Spain). Images
were acquired with a confocal laser-scanning microscope (Model
A1, Nikon Instruments Europe BV, Amsterdam, Netherlands).
2.10. Data analysis
The datawere analyzedwith the SigmaPlot 12.0 program (Systat
Software Inc., San Jose, CA, USA). Two-way repeated-measures
analysis of variance (ANOVA) or one-way ANOVA were used
depending on the experiment. The StudenteNewmaneKeuls post-
test was used in all cases. The differences between means were
considered significant when the P value was below 0.05.
3. Results
3.1. Behavioral phenotyping of mice with CFA-induced joint
inflammation: grip strength, mechanical allodynia, body weight and
locomotor activity
The administration of 20 or 30 mL/ankle of CFA induced volume-
dependent decreases in hindlimb grip strength (about 35% for 20 mL
and 55% for 30 mL) during the first 3 days after the induction of
inflammation. In both dose groups, grip strength values returned to
normal levels, although the recovery period was longer in animals
given the higher volume of CFA (Fig. 1A). Untreated (naïve) animals
and mice treated periarticularly with saline (30 mL/ankle) did not
show significant changes in grip strength at any time-point tested
for up to 21 days (Fig. 1A).
CFA induced persistent ankle swelling that lasted for at least 21
days, which was also dependent on the volume administered.
Fig. 1. Grip strength deficits in mice given periarticular injections of CFA were accompanied by edema and localized immune infiltrate. (A) Time-course of hindlimb grip strength in
animals treated with CFA (20 or 30 mL/ankle), compared to naïve mice and animals treated with saline (30 mL/ankle). (B) Increase in ankle thickness after the administration of CFA
or saline (20 or 30 mL/ankle). (C) Representative pictures of mice treated periarticularly with 30 mL/ankle of saline or CFA (left and right panels, respectively). (D) Representative
photomicrographs of hematoxylin and eosin-stained tibiotarsal joint, synovial membrane and paw pad in mice after the administration of saline or CFA (30 mL/ankle); the scale bars
represent 200 mm in all panels. Values are the mean ± SEM (10e12 animals per group). Statistically significant differences in (A) and (B): **P < 0.01 versus the values from naïve
animals (two-way repeated measures ANOVA in (A) and one-way ANOVA in (B) both followed by StudenteNewmaneKeuls test). There were no statistically significant differences
between values from naïve animals and saline-treated mice. Data for ankle swelling and histological analyses were obtained from the same mice.
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those given 20 mL, whereas those treated with saline (30 mL/ankle)
showed no significant increase in ankle thickness (Fig. 1B). We used
30 mL CFA (or saline)/ankle in the rest of the experiments. Macro-
scopically, saline-treated animals showed no signs of paw inflam-
mation (Fig. 1C, left panel). However, CFA-treated mice had
prominent inflammation that appeared to be restricted to the
administration site (ankle joint) and nearby areas, whereas the pawpad did not appear to be affected (Fig. 1C right panel). Histological
examination of the tibiotarsal joint, synovial membrane or paw pad
frommice 2 days after the administration of saline did not disclose
any histological anomalies (Fig. 1D upper panels); however, 2 days
after CFA administration we found massive periarticular immune
infiltrate which extended to the heel, as well as an inflammatory
process in the synovial membrane characterized by prominent
immune infiltrate accompanied by intraarticular exudate, but no
A. Montilla-García et al. / Neuropharmacology 125 (2017) 231e242 235histological alterations in the paw pad (Fig. 1D, middle panels).
Twenty-one days after CFA administration, the animals still showed
marked immune infiltration in the heel and periarticular struc-
tures, but the synovial membrane showed no immune infiltrate,
and we did not observe appreciable intraarticular exudate, and the
paw pad remained unaffected (Fig. 1D, lower panels).
We then measured the mechanical threshold in an inflamed
(heel) and in a noninflamed area (pad) of the paw. Mice given CFA
showed a marked decrease in the von Frey threshold in the heel,
denoting the presence of tactile allodynia, and the decrease was
maintained throughout the time-course of study (21 days) (Fig. 2A).
Joint inflammation did not induce alterations in the mechanical
threshold in the paw pad (Fig. 2A), indicating that the sensory al-
terations appeared to be restricted to the inflamed area. Control
mice treated periarticularly with saline showed no alterations in
their mechanical thresholds in either the heel or the paw pad
(Fig. 2A).
We also determined whether joint inflammation under our
experimental conditions induced other alterations such as changes
in body weight or locomotion. Animals with induced inflammation
showed no changes in body weight in comparison to saline-treated
mice (Fig. 2B). In addition, CFA administration did not induce al-
terations in either vertical or horizontal locomotor activity in
comparison to control mice (Fig. 2C). Therefore, this indicates that
although CFA administration induced an apparent decrease in grip
strength andmechanical threshold, it did not significantly affect the
animals’ general state or general mobility.3.2. Effects of conventional oral analgesics on inflammation-
induced grip strength deficits and tactile allodynia
To test whether grip strength deficits were related to pain, we
evaluated the effects of conventional analgesics. Oral administra-
tion of the NSAIDs ibuprofen and celecoxib, as well as acetamino-
phen, produced a dose-dependent increase in grip strength in
animals with joint inflammation (Fig. 3A, B and C, respectively). The
maximum effect of all three drugs peaked at 90 min after admin-
istration, but even at this time-point grip strength in mice with
induced inflammation failed to fully recover basal values. Subse-
quently, the increase in grip strength in animals with jointFig. 2. Mechanical allodynia in mice given periarticular injections of CFA did not parallel alte
paw pad in mice treated periarticularly with CFA or saline. (B) Time-course of body weight
traveled) locomotor activity of naïve mice and CFA-treated animals, 1 or 2 days after the
periments. Values are the mean ± SEM (10e12 animals per group). Statistically significa
inflammation stimulated in the heel at each time-point (two-way repeated measures ANOV
between values from saline- or CFA-treated animals at any time-point tested (two-way repe
naïve- or CFA-treated animals (one-way ANOVA).inflammation induced by the NSAIDs or acetaminophen gradually
reverted (Fig. 3A, B and C). We also tested the effects of oral
administration of the opioids tramadol and oxycodone (Fig. 4A and
B, respectively). These drugs induced a rapid recovery of physical
function peaking at 45 min after administration, which decreased
gradually with time. In contrast to the effects of NSAIDs or acet-
aminophen, both tramadol and oxycodone induced full recovery
from grip strength deficits in mice with joint inflammation (Fig. 4A
and B, respectively). None of these analgesics was able to modify
grip strength values in animals without inflammation, even when
administered at doses that had maximal effects in mice with
induced inflammation (Fig. 3A, B and C and Fig. 4A and B). These
results suggest that the analgesics tested improved grip strength
deficits by pain-specific effects rather than by altering normal
motor function.
We then constructed the dose-response curves of drug effects
at their time of maximum effect (90 min for the NSAIDs and
acetaminophen, and 45 min for the opioid drugs), to facilitate
comparisons of the effects of different drugs on the recovery of
grip strength in mice with joint inflammation. Maximal effects of
ibuprofen, celecoxib and acetaminophen led to a recovery of grip
strength of about 60% of pre-inflammation values, whereas in
animals treated with the opioids oxycodone or tramadol, grip
strength recovered to approximately 90% of control values
(Fig. 5A).
We then tested the effects of all drugs on tactile allodynia in
mice with induced inflammation. Doses of ibuprofen, celecoxib,
acetaminophen or tramadol that induced z60% recovery of grip
strength (40 mg/kg, 80 mg/kg, 160 mg/kg and 20 mg/kg, respec-
tively) were devoid of effect on tactile allodynia at any time-point
tested between 45 and 240 min (Suppl Fig. 1A for NSAIDs and
acetaminophen, and Suppl Fig. 1B for tramadol). On the other hand,
oxycodone 4 mg/kg induced a modest but significant amelioration
of mechanical allodynia at 45 min (Suppl Fig. 1B), which coincided
with its peak effect on grip strength deficits (Fig. 4B). This effect
rapidly disappeared, which is in contrast to the longer duration of
its effects on grip strength deficits, which lasted for 90 min (Suppl
Fig. 1B and Fig. 4B). To facilitate comparisons of the effects of these
drugs on the recovery of grip strength and mechanical allodynia
only the time-point of 90 min for the NSAIDs and acetaminophen,rations in body weight or locomotor activity. (A) von Frey threshold in the heel and the
after the administration of CFA or saline. (C) Vertical (rears) and horizontal (distance
induction of periarticular inflammation. A volume of 30 mL/ankle was used in all ex-
nt differences in: (A) **P < 0.01 between the values from mice with and without
A followed by StudenteNewmaneKeuls test); (B) no statistically significant differences
ated measures ANOVA); (C) no statistically significant differences between values from
Fig. 3. Effects of oral NSAIDs and acetaminophen on grip strength deficits induced by the periarticular administration of CFA. Ibuprofen (A), celecoxib (B), acetaminophen (C) or
their solvents (HPMC for ibuprofen, and 1% Tween 80 in HPMC for celecoxib and acetaminophen) were given orally (p.o.) 2 days after the administration of CFA or saline (30 mL/
ankle). Values are the mean ± SEM (10e12 animals per group). Statistically significant differences in (A), (B) and (C): *P < 0.05 between the values from mice with inflammation
treated with the drug or solvent at each time-point; #P < 0.05 between the values from mice without inflammation treated with the drug solvents and mice with inflammation at
each time-point (two-way repeated measures ANOVA followed by StudenteNewmaneKeuls test). For clarity, significances of P < 0.01 are not labeled with double symbols. There
were no significant differences between mice without inflammation treated with the drugs or their solvents at any time-point tested.
A. Montilla-García et al. / Neuropharmacology 125 (2017) 231e242236and 45 min for the opioid drugs, are shown in Fig. 5B. When we
doubled the doses of these drugs all of them were then able to
ameliorate tactile allodynia (Fig. 5B). Therefore, although all anal-
gesics tested were able to improve both physical function and
tactile allodynia, grip strength was a more sensitive indicator of
drug-induced analgesia than tactile allodynia.Fig. 4. Effects of oral opioids on grip strength deficits induced by the periarticular administ
orally (p.o.) 2 days after the administration of CFA or saline (30 mL/ankle). Values are the me
*P < 0.05 between the values from mice with inflammation treated with the drug or solve
treated with the drug solvents and mice with inflammation at each time-point (two-way r
nificances of P < 0.01 are not labeled with double symbols. There were no significant differen
time-point tested.3.3. Effects of the muscle relaxant baclofen on inflammation-
induced grip strength deficits and mechanical allodynia
To determine the impact of motor impairment on grip strength
and tactile allodynia, we tested the effects of the muscle relaxant
baclofen. This drug induced opposite effects on grip strength andration of CFA. Tramadol (A), oxycodone (B) or their solvent (HPMC) were administered
an ± SEM (10e12 animals per group). Statistically significant differences in (A) and (B):
nt at each time-point; #P < 0.05 between the values from mice without inflammation
epeated measures ANOVA followed by StudenteNewmaneKeuls test). For clarity, sig-
ces between mice without inflammation treated with the drugs or their solvents at any
Fig. 5. Comparison of the effects induced by the oral administration of analgesic drugs
on grip strength deficits and tactile allodynia in mice treated periarticularly with CFA.
(A) Effects of analgesic drugs on grip strength deficits and (B) on the von Frey threshold
in the heel of animals with inflammation. In all cases, drugs or their solvents were
administered orally (p.o.) 2 days after CFA administration (30 mL/ankle). HPMC was
used as the solvent for ibuprofen, tramadol and oxycodone (white symbols), and 1%
Tween 80 in HPMC for celecoxib and acetaminophen (black symbols). Values are the
mean ± SEM (10e12 animals per group). Data are expressed as the percent recovery of
grip strength or percent antiallodynic effect, considering as 0% effect the values ob-
tained immediately before drug administration, and a 100% effect the values obtained
before CFA injection in each individual mouse. Values were obtained 45 min after
tramadol or oxycodone administration, or 90 min after ibuprofen, celecoxib, or acet-
aminophen administration. Statistically significant differences in (A) and (B): *P < 0.05,
**P < 0.01 between the values from mice with inflammation treated with the drugs or
their solvents (one-way ANOVA followed by StudenteNewmaneKeuls test).
Fig. 6. Comparison of the effects induced by the oral administration of baclofen on
grip strength deficits and tactile allodynia in mice treated periarticularly with CFA.
Baclofen or its solvent (HPMC) was administered orally (p.o.) 2 days after CFA
administration (30 mL/ankle). Values are the mean ± SEM (10e12 animals per group).
The data are expressed as the percent recovery of grip strength or percent anti-
allodynic effect, considering the values obtained immediately before drug adminis-
tration as 0%, and the values obtained before CFA injection in each individual mouse as
100%. All values were obtained 45 min after the administration of baclofen or its
solvent. Statistically significant differences: *P < 0.05, **P < 0.01 between the values
from mice with inflammation treated with the drugs or their solvents (one-way
ANOVA followed by StudenteNewmaneKeuls test).
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threshold in mice with inflammation, inducing a marked
antiallodynic-like effect (to an extent similar to oxycodone), and
did not ameliorate grip strength deficits, but induced a parallel
decrease in this functional measure (Fig. 6). In addition, the active
doses of baclofen also decreased grip strength in noninjured ani-
mals (data not shown).3.4. Effects of the TRP antagonist ruthenium red on inflammation-
induced grip strength deficits and mechanical allodynia
We also evaluated whether grip strength deficits and mechan-
ical allodynia during inflammation were sensitive to the TRP
antagonist ruthenium red. The systemic administration of thiscompound (1e2 mg/kg) did not affect grip strength in injured or
noninjured mice at any time-point tested between 30 and 180 min
(Suppl. Fig. 2). For clarity, only the data for 2 mg/kg 30 min post-
administration are shown in Fig. 7A. However, ruthenium red
(administered 30 min before the behavioral evaluation) was able to
abolish, in a dose-dependent manner, mechanical allodynia in mice
with inflammation but without affecting the mechanical threshold
in noninjured mice (Fig. 7B). We were unable to test a higher dose
of ruthenium red (4 mg/kg) because it induced prominent side
effects. The differential effects of ruthenium red on grip strength
deficits and tactile allodynia suggest that their mechanisms differ.3.5. Contribution of TRPV1-expressing neurons to inflammation-
induced grip strength deficits and tactile allodynia
To investigate whether grip strength deficits and mechanical
allodynia during inflammation depend on the same type of noci-
ceptive neurons, we compared the effects on grip strength and
mechanical threshold of the in vivo ablation of TRPV1-expressing
neurons. TRPV1 staining is present in the somas of small DRG
neurons and in the superficial layers of the spinal cord dorsal horn
(see controls in Fig. 8A and B, respectively). After RTX treatment we
were unable to detect TRPV1 staining in either the DRG (Fig. 8A) or
the spinal cord dorsal horn (Fig. 8B), reflecting the ablation of
TRPV1-expressing neurons including their central terminals. The
ablation of this nociceptive population did not affect either grip
strength ormechanical threshold in noninjuredmice (Fig. 8C and D,
respectively). However, it was able to prevent the development of
mechanical allodynia inmicewith inflammation (Fig. 8D), although
it had no effect on their grip strength deficits (Fig. 8C). Therefore,
grip strength deficits and the decrease in the von Frey threshold
during joint inflammation involve the participation of different
populations of primary afferents.4. Discussion
In this study we show that in mice with experimentally-induced
joint inflammation, grip strength decreased markedly and for a
Fig. 7. Effects of the subcutaneous administration of ruthenium red on grip strength deficits and von Frey threshold in mice treated periarticularly with CFA. (A) Absence of effect of
ruthenium red (RR) on grip strength deficits induced by CFA. (B) RR, administered 30 min before the behavioral evaluation, attenuated the decrease in von Frey threshold induced by
CFA. RR or its solvent (saline) was administered subcutaneously (s.c.) 2 days after CFA administration (30 mL/ankle). Values are the mean ± SEM (10e12 animals per group).
Statistically significant differences in (A) and (B): **P < 0.01 between the values from mice with and without inflammation treated with ruthenium red or its solvent; ##P < 0.01
between the values from mice with inflammation treated with ruthenium red or its solvent (one-way ANOVA followed by StudenteNewmaneKeuls test).
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(measured with von Frey filaments) in the inflamed area differed in
both their time-courses of evolution and in their sensitivity to
conventional analgesics. In addition, we show that although tactile
allodynia was abolished by ruthenium red or by the ablation of
TRPV1-expressing neurons, deficits in grip strength in mice with
joint inflammation were not.
The time-courses of recovery from grip strength deficits and
mechanical allodynia differed, as the latter persisted longer than
the functional deficit. The different time-courses of evolution in
these two outcomes indicate that pronounced tactile hypersensi-
tivity in the inflamed area does not necessarily imply a significant
alteration in physical function. We show that the periarticular
administration of CFA in the ankle joint induced prominent, long-
lasting ankle swelling. However, this sustained ankle swelling
was accompanied by histological alterations which differed in
duration. Both the inflammatory process in the synovial membrane
(i.e. immune infiltrate and intraarticular exudates) and grip
strength deficits were prominent 2 days after inflammation was
induced, whereas they both became attenuated 21 days after CFA
injection. These results suggest that synovial membrane alterations
may be related to the functional deficits observed, and in this
connection, synovitis has been strongly linked to both joint
dysfunction and pain in human studies (reviewed in Rice et al.,
2015; Scanzello and Goldring, 2012; Scott et al., 2000). Under our
experimental conditions, the immune infiltrate in mice with
inflammation extended to the heel and was prominent throughout
the entire study period, as was mechanical allodynia in this area of
the paw (in contrast to the recovery of the synovial membrane and
grip strength). The persistent immune infiltrate in the heel may
contribute to the long-lasting tactile hypersensitivity we detected
in our mice, as it is known that immune cells play a pivotal role in
inflammatory cutaneous allodynia (Ghasemlou et al., 2015). These
results suggest that the histological alterations which drive func-
tional deficits and tactile allodynia may differ. We did not detect
either observable histological or sensory alterations in the paw pad
of mice with periarticular CFA-induced inflammation. Of note
regarding this observation is that mice gripped the metal barconnected to the force transducer with this part of the paw, and
therefore, the deficits seen in grip strength in animals with
inflammation cannot be ascribed to alterations in paw pad sensi-
tivity (as mice do not develop allodynia in this area) but is instead
likely to be the result of movement or tension in the inflamed joint
during gripping.
Pain states can curtail body weight gain of rodents (Blackburn-
Munro, 2004) and their exploratory activity, particularly their
vertical activity (rearing) when the lower limbs are injured
(reviewed by Cobos and Portillo-Salido, 2013). We found that mice
with joint inflammation, despite their marked grip strength defi-
cits, did not show alterations in body weight gain or exploratory
activity. These results indicate that grip strength deficits are a more
sensitive indicator of functional alterations than other pain-related
outcomes.
To test whether the decrease in grip strength was related to
pain, we investigated the effects of orally administered analgesics
used for clinical treatment in humans. The NSAIDs ibuprofen and
celecoxib, as well as acetaminophen, induced a significant but
limited recovery from grip strength deficits. However, the opioids
tramadol and oxycodone were able to completely reverse the
functional deficit induced by joint inflammation. The higher effi-
cacy of opioids in comparison to NSAIDs or acetaminophen in the
recovery of grip strength is in agreement with the analgesic efficacy
of these drugs in human patients, according to the WHO analgesic
ladder (Sarzi-Puttini et al., 2012); therefore the alterations in grip
strength during joint inflammation in our experimental animals are
largely attributable to pain. This link between pain and grip
strength deficits in mice agrees with the known correlation be-
tween pain and disability according to the same outcome measure
in patients with joint pain (e.g. Fraser et al., 1999; Overend et al.,
1999). Sensitivity to analgesic treatment differed between grip
strength recovery andmechanical allodynia: the formerwas amore
sensitive indicator of the effects of analgesic drugs than the latter.
To the best of our knowledge, the different sensitivities of tactile
hypersensitivity and grip strength deficits to the effects of drugs
have not been explored in earlier research that used grip strength
as a pain outcome measure. The greater sensitivity of grip strength
Fig. 8. Differential effects of the ablation of TRPV1-expressing neurons on grip strength deficits and von Frey threshold in mice treated periarticularly with CFA. (A) and (B) Double
labeling of NeuN (red) and TRPV1 (green) in the L4 dorsal root ganglion (DRG) and in the spinal cord (SC) lumbar enlargement from CFA-treated mice. Top panels: samples from
saline-treated mice (control). Bottom panels: samples from mice treated with resiniferatoxin (RTX). The scale bars represent 100 mm. (C) Absence of effect of RTX on grip strength
deficits induced by CFA. (D) RTX attenuated the decrease in von Frey threshold induced by CFA. Sample collection and behavioral testing were done 2 days after the periarticular
administration of CFA or saline (30 mL/ankle), in mice treated with RTX (50 mg/kg) or its solvent. Values are the mean ± SEM (10e12 animals per group). Statistically significant
differences in (C) and (D): **P < 0.01 between the values from mice with and without inflammation treated with RTX or its solvent; ##P < 0.01 between the values from mice with
inflammation treated with RTX or its solvent (one-way ANOVA followed by StudenteNewmaneKeuls test). The same mice were used for the behavioral and immunofluorescence
assays.
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induced analgesia is in agreement with previous studies with
other measures of physical functioning in rodents, such as changes
in weight bearing in the injured paw, exploratory locomotion,
burrowing behavior or wheel running (Andrews et al., 2012; Cobos
et al., 2012; Huntjens et al., 2009; Matson et al., 2007). Therefore,
the greater sensitivity to drug-induced analgesia may be aninherent quality of these types of more “natural” pain measures, as
previously suggested (Cobos and Portillo-Salido, 2013; De la Puente
et al., 2015). This might be particularly relevant for analgesic drug
discovery, because many new potentially interesting compounds
are discarded based on their lack of efficacy on tactile allodynia,
although they might ameliorate functional measures of pain which
currently are not routinely evaluated.
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strength in animals without inflammation, and therefore the re-
covery of grip strength inmicewith joint inflammationwas not due
to nonspecific drug effects on normal grip strength.
Drugs may inhibit pain-like reflexes due to sedative and motor
effects, resulting in false-positive results. Here we show that bac-
lofen induced a marked increase in the von Frey threshold in mice
with inflammation, and its effect was similar to that of the third-
step opioid oxycodone. However, we found that “antiallodynic”
doses of this drug also decreased grip strength in mice with and
without inflammation. This suggests that the effects induced by
baclofen on inflammatory mechanical allodynia are due to this
drug's known motor impairment and sedative effects (Dario and
Tomei, 2004) rather than to a true analgesic effect. Therefore, grip
strength and von Frey threshold are not affected in the sameway by
the same confounders. Whereas drug-induced motor impairment
might lead to a false analgesic-like effect in the von Frey test, it
would not be expected to have this effect in tests of grip strength as
a surrogate measure of pain. For analgesic drug discovery it is
essential to determine whether drugs induce signs of toxicity. Grip
strength has been used in humans to test drug-induced toxicity
(Savilampi et al., 2014) it is classically used to assess neurotoxicity
in rodents (Meyer et al., 1979) and is even included in the Irwin
screen (Irwin, 1968; Mattsson et al., 1996) which is ingrained in the
pharmaceutical industry as the first tier of preclinical testing to
detect drug-induced neurotoxic effects (Moser, 2011). Therefore,
this outcome measure can be used to detect both drug-induced
analgesia and toxicity, which is undoubtedly advantageous to
determine the therapeutic index of drugs being tested during
preclinical development.
The different responses of grip strength deficits and tactile
allodynia to analgesic treatment, together with the previously
noted differences in their time-courses, support the notion that
different mechanisms are involved in the appearance of mechanical
allodynia and joint pain-induced functional disability. In fact, we
show that the nonselective TRP antagonist ruthenium red was able
to abolish inflammatory tactile allodynia but without ameliorating
grip strength deficits. Our results using ruthenium red agree with
its previously reported effects on tactile allodynia from diverse
etiology (Cui et al., 2014; Qu et al., 2016; Shinoda et al., 2008).
Ruthenium red is a widely used TRP antagonist (e.g. St Pierre et al.,
2009), although it also blocks other channels, including the
mechanosensitive Piezo channels (Coste et al., 2012). Therefore,
although our results indicate that tactile allodynia and grip
strength deficits are not affected in the sameway by this compound
(and hence suggest that their mechanisms differ), this does not
definitively link TRP channels to the effects we observed.
We then targeted the function of TRPV1þ neurons, which are
known to express several TRP channels (Julius, 2013). In our study
the ablation of these TRPV1-expressing sensory neurons did not
alter the normal mechanical threshold, but completely attenuated
tactile allodynia, which is consistent with the known pivotal role of
TRPV1 neurons in cutaneous pain hypersensitivity during inflam-
matory arthritis (Borbely et al., 2015). However, we found no effect
on joint inflammation-induced grip strength deficits, indicating
that TRV1-expressing neurons are not responsible for the func-
tional deficits observed. Grip strength has been previously used as
an indicator of pain-induced disability in osteoarthritic pain
(Chandran et al., 2009; Honore et al., 2009). It has been reported
that TRPV1 antagonism is able to ameliorate grip strength deficits
in rodents with experimental osteoarthritis (Honore et al., 2009).
Osteoarthritis has been classically considered a “noninflammatory
arthritis” (e.g. Haroon et al., 2016), and although it is currently
believed that osteoarthritis has an inflammatory component
(Sokolove and Lepus, 2013), this is not as prominent as in our CFA-treated mice. Therefore, the differences between our findings and
previous reports might be due to differences in the type of joint
pain explored.
TRPV1 is present in nearly all unmyelinated (C-type) peptidergic
neurons in the mouse DRG (Cavanaugh et al., 2011), but is almost
absent from A-neurons and virtually absent from C-nonpeptidergic
nociceptors (e.g. Cavanaugh et al., 2011; Niiyama et al., 2007).
Therefore, other nociceptive neurons different from C-peptidergic
nociceptors, such as Ad or C-nonpeptidergic neurons (which ex-
press little or noTRPV1) (e.g. Niiyama et al., 2007), might contribute
to grip strength deficits during joint inflammation. An alternative
explanation is that joint tissues are also innervated by pro-
prioceptors, which under painful conditions might lead to pain via
central mechanisms (e.g. Mapp, 1995). Regardless of the exact
mechanism involved in grip strength deficits during joint inflam-
mation, the differential effects of ruthenium red and the ablation of
TRPV1-expressing neurons on tactile allodynia and functional
disability during joint inflammation strongly support the notion
that their biological mechanisms differ.
5. Conclusions
We conclude that monitoring grip strength deficits during
joint inflammation is a reliable measure of inflammatory joint
pain in rodents, as it is known to be in humans. Grip strength can
be used to characterize the efficacy of analgesic treatment as well
as the appearance or severity of drug-induced neurotoxic effects
(a prominent confounder in preclinical analgesia development),
and can be readily used by academic laboratories as well as by the
pharmaceutical industry. The neurobiological mechanisms
involved in grip strength deficits and tactile allodynia during
inflammation differ, and therefore the results obtained with
measures of cutaneous hypersensitivity alone in preclinical drug
testing cannot be directly extrapolated to inflammatory joint
pain-induced functional impairment. The evaluation of grip
strength deficits holds potential to improve the reliability of
preclinical evaluations of new pain targets and candidate anal-
gesics by providing a measure in rodents of a parameter widely
used in the clinical practice.
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